StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
DelistingJul 30, 2026, 04:08 PM

Curis Regains Nasdaq Compliance, Subject to 1-Year Monitor

AI Summary

Curis, Inc. announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Bid Price Rule, and is in full compliance with the Nasdaq Hearings Panel's terms as of July 24, 2026. However, the company will be subject to a Discretionary Panel Monitor for one year. During this period, any failure to maintain compliance will result in a delist determination without the usual opportunity to provide a compliance plan or receive additional time.

Key Highlights

  • Curis regained compliance with Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule).
  • Company is in full compliance with Nasdaq Hearings Panel terms as of July 24, 2026.
  • Subject to a Discretionary Panel Monitor for a one-year period from July 24, 2026.
  • During monitor, no compliance plan or additional time for new deficiencies will be permitted.
  • No assurance that the company will remain listed on Nasdaq.